Cardlytics (NASDAQ:CDLX) Rating Lowered to “Sell” at Wall Street Zen

Cardlytics (NASDAQ:CDLX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other research analysts have also issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a research report on Thursday, June 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Cardlytics in a report on Wednesday, July 8th. One equities research analyst has rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Cardlytics presently has an average rating of “Sell” and an average target price of $10.00.

Cardlytics Stock Performance

Shares of Cardlytics stock opened at $3.75 on Friday. Cardlytics has a 52 week low of $3.49 and a 52 week high of $32.80. The stock has a market cap of $21.79 million, a PE ratio of -0.20 and a beta of 0.67. The company’s 50-day moving average price is $3.98 and its two-hundred day moving average price is $6.17.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.30) by $0.80. Cardlytics had a negative net margin of 55.92% and a negative return on equity of 956.56%. The company had revenue of $36.88 million for the quarter, compared to analysts’ expectations of $37.00 million. On average, equities analysts predict that Cardlytics will post -3.89 EPS for the current fiscal year.

Insider Activity

In related news, CEO Amit Gupta sold 6,676 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $4.03, for a total value of $26,904.28. Following the completion of the sale, the chief executive officer owned 125,389 shares in the company, valued at approximately $505,317.67. This represents a 5.06% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold a total of 31,750 shares of company stock worth $134,129 in the last quarter. 5.90% of the stock is owned by insiders.

Institutional Trading of Cardlytics

A hedge fund recently bought a new stake in Cardlytics stock. Worldly Partners Management LLC bought a new stake in Cardlytics, Inc. (NASDAQ:CDLX) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 115,798 shares of the company’s stock, valued at approximately $520,000. Cardlytics makes up approximately 0.4% of Worldly Partners Management LLC’s investment portfolio, making the stock its 3rd largest position. Worldly Partners Management LLC owned approximately 1.99% of Cardlytics as of its most recent SEC filing. Institutional investors own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc is an advertising technology company that connects marketers with consumers through financial institutions. Its platform uses transaction-based insights to help advertisers reach customers with relevant offers and measure the impact of advertising on consumer spending.

Cardlytics’ services are integrated into banking and financial applications, where consumers may receive personalized cash-back offers, discounts and other promotions based on their shopping activity. Participating financial institutions can use the platform to provide additional value to customers while generating advertising revenue.

The company serves advertisers across categories such as retail, dining, travel and financial services, and works with banks and other financial institutions primarily in the United States and the United Kingdom.